Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: Actinium-225-DOTATATE and Combined Therapies.
(225)Ac-DOTATATE
Capecitabine
GEP-NETs
Neuroendocrine tumors
PRRT
Peptide receptor radionuclide therapy
Targeted alpha therapy
Temozolomide
Journal
PET clinics
ISSN: 1879-9809
Titre abrégé: PET Clin
Pays: United States
ID NLM: 101260152
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
entrez:
1
3
2023
pubmed:
2
3
2023
medline:
4
3
2023
Statut:
ppublish
Résumé
The role of lutetium-177-DOTATATE in advanced well-differentiated gastro-entero-pancreatic neuroendocrine tumors is well established. However, there is a scope for improving treatment outcomes. Actinium-225-DOTATATE is a form of targeted alpha therapy (TAT) that results in more efficient tumor cell killing owing to the substantially higher linear energy transfer of alpha particles. Systemic TAT is also safe given that the shorter path length of the alpha particles spares the surrounding healthy tissue and results in relatively fewer adverse events. Combination therapies with radiosensitizing and other chemotherapeutic agents have also gained popularity, especially in the setting of higher grade and fluorodeoxyglucose-avid tumors.
Identifiants
pubmed: 36858746
pii: S1556-8598(22)00091-8
doi: 10.1016/j.cpet.2022.11.004
pii:
doi:
Substances chimiques
Actinium-225
0
copper dotatate CU-64
0
Actinium
NIK1K0956U
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
215-221Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.